BINTA BEARD

H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 H.R.7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage. 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 H.R.7647, To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 H.R. 5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 Biopharmaceutical innovation and patent policy issues S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Patent litigation reform issues and issues related to post-grant proceedings at the PTO Value of intellectual property

H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues H.R. 6201, Families First Coronavirus Response Act - provisions related to health care 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues

H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions H.R. 19: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895: Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates S. 3129: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13938, White House Executive Order on Increasing Drug Importation to Lower Prices for American Patients Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements

H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates S. 3129, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements (CMS 2482-F) CMS Most Favored Nation (MFN) Model interim final rule (MFN Rule), implementing President Trump's proposal to align drug prices in the United States with those available in economically similar countries

H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues H.R. 6201, Families First Coronavirus Response Act - provisions related to health care 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues

H.R. 2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill 2020 - HHS provisions related to prescription drugs FY 2020 Omnibus Appropriations Bill - Provisions relating to biopharmaceutical products

H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions H.R. 19: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895: Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates S. 3129: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13938, White House Executive Order on Increasing Drug Importation to Lower Prices for American Patients Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements

H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues H.R. 6201, Families First Coronavirus Response Act - provisions related to health care 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 H.R. 5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 Biopharmaceutical innovation and patent policy issues S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Patent litigation reform issues and issues related to post-grant proceedings at the PTO Value of intellectual property

H.R.5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 S.1416, Affordable Prescriptions for Patients Act of 2019 Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 H.R. 5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 Biopharmaceutical innovation and patent policy issues S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Patent litigation reform issues and issues related to post-grant proceedings at the PTO Value of intellectual property

H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues H.R. 6201, Families First Coronavirus Response Act - provisions related to health care 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues

H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 H.R.7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage. 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 H.R.7647, To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 H.R.7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage. 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 H.R.7647, To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

H.R.5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 S.1416, Affordable Prescriptions for Patients Act of 2019 Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 H.R. 5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 Biopharmaceutical innovation and patent policy issues S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Patent litigation reform issues and issues related to post-grant proceedings at the PTO Value of intellectual property

H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues H.R. 6201, Families First Coronavirus Response Act - provisions related to health care 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues

H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates S. 3129, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements (CMS 2482-F) CMS Most Favored Nation (MFN) Model interim final rule (MFN Rule), implementing President Trump's proposal to align drug prices in the United States with those available in economically similar countries

H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions H.R. 19: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895: Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates S. 3129: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13938, White House Executive Order on Increasing Drug Importation to Lower Prices for American Patients Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements

S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements

H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates S. 3129, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements (CMS 2482-F) CMS Most Favored Nation (MFN) Model interim final rule (MFN Rule), implementing President Trump's proposal to align drug prices in the United States with those available in economically similar countries

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Medicare Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions H.R. 19: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895: Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates S. 3129: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13938, White House Executive Order on Increasing Drug Importation to Lower Prices for American Patients Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements

S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements

H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions H.R. 19: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895: Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates S. 3129: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13938, White House Executive Order on Increasing Drug Importation to Lower Prices for American Patients Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Medicare Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates S. 3129, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements (CMS 2482-F) CMS Most Favored Nation (MFN) Model interim final rule (MFN Rule), implementing President Trump's proposal to align drug prices in the United States with those available in economically similar countries

H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions H.R. 19: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895: Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates S. 3129: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13938, White House Executive Order on Increasing Drug Importation to Lower Prices for American Patients Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements

H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates S. 3129, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements (CMS 2482-F) CMS Most Favored Nation (MFN) Model interim final rule (MFN Rule), implementing President Trump's proposal to align drug prices in the United States with those available in economically similar countries

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Medicare Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs - Provisions related to Medicaid rebates H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P Proposed Rule: OIG-0936-P Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 475, RxCAP Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference and rebates policy issues CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P Proposed Rule: OIG-0936-P Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Medicare Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Medicare Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs - Provisions related to Medicaid rebates H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P Proposed Rule: OIG-0936-P Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 475, RxCAP Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference and rebates policy issues CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P Proposed Rule: OIG-0936-P Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P

S. 64, Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings Act of 2019 - Provisions related to patent settlements H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 H.R. 5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 Biopharmaceutical innovation and patent policy issues S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements Biopharmaceutical innovation and patent policy issues S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

S. 64, Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings Act of 2019 - Provisions related to patent settlements H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures S. 1224, Stop STALLING Act - Provisions related to citizen petitions S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

S. 64, Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings Act of 2019 - Provisions related to patent settlements H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures S. 1224, Stop STALLING Act - Provisions related to citizen petitions S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures S. 1224, Stop STALLING Act - Provisions related to citizen petitions S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to Medicare Part D and prescription drug pricing H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues

S. 64, Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings Act of 2019 - Provisions related to patent settlements H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

HR. 3, Lower Drug Costs Now Act of 2019 - provisions related to non-interference, International Pricing Index Model and Medicare part D H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues CMS-9926-F: Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2020, Final rule

H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 -Provisions related to wholesale acquisition costs of prescription drugs S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues

S. 64, Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings Act of 2019 - Provisions related to patent settlements H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures S. 1224, Stop STALLING Act - Provisions related to citizen petitions S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to Medicare Part D and prescription drug pricing H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues

H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to Medicare Part D and prescription drug pricing H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues

HR. 3, Lower Drug Costs Now Act of 2019 - provisions related to non-interference, International Pricing Index Model and Medicare part D H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues CMS-9926-F: Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2020, Final rule

H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 -Provisions related to wholesale acquisition costs of prescription drugs S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues

H.R. 2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill 2020 - HHS provisions related to prescription drugs

H.R. 2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill 2020 - HHS provisions related to prescription drugs

H.R. 2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill 2020 - HHS provisions related to prescription drugs FY 2020 Omnibus Appropriations Bill - Provisions relating to biopharmaceutical products

HR. 3, Lower Drug Costs Now Act of 2019 - provisions related to non-interference, International Pricing Index Model and Medicare part D H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues CMS-9926-F: Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2020, Final rule

H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to Medicare Part D and prescription drug pricing H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 H.R. 5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 Biopharmaceutical innovation and patent policy issues S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 H.R. 5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 Biopharmaceutical innovation and patent policy issues S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 H.R. 5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 Biopharmaceutical innovation and patent policy issues S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

H.R. 965, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures S. 1224, Stop STALLING Act - Provisions related to citizen petitions S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures S. 1224, Stop STALLING Act - Provisions related to citizen petitions S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 H.R. 5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 Biopharmaceutical innovation and patent policy issues S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements Biopharmaceutical innovation and patent policy issues S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

HR. 3, Lower Drug Costs Now Act of 2019 - provisions related to non-interference, International Pricing Index Model and Medicare part D H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues CMS-9926-F: Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2020, Final rule

H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 -Provisions related to wholesale acquisition costs of prescription drugs S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues

H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to Medicare Part D and prescription drug pricing H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Medicare Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Medicare Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 475, RxCAP Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference and rebates policy issues CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P Proposed Rule: OIG-0936-P Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees

H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to Medicare Part D and prescription drug pricing H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues

HR. 3, Lower Drug Costs Now Act of 2019 - provisions related to non-interference, International Pricing Index Model and Medicare part D H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues CMS-9926-F: Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2020, Final rule

H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 -Provisions related to wholesale acquisition costs of prescription drugs S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Medicare Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 475, RxCAP Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference and rebates policy issues CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P Proposed Rule: OIG-0936-P Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs - Provisions related to Medicaid rebates H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P Proposed Rule: OIG-0936-P Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 475, RxCAP Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference and rebates policy issues CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P Proposed Rule: OIG-0936-P Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees

S. 64, Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings Act of 2019 - Provisions related to patent settlements H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures S. 1224, Stop STALLING Act - Provisions related to citizen petitions S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

S. 64, Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings Act of 2019 - Provisions related to patent settlements H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

H.R. 4117: Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017 - Patent Settlements H.R. 5340: The Support Technology & Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act of 2018 - Provisions related to reforms of Patent Trial and Appeal Board (PTAB) proceedings and other patent system reforms S. 124: Preserve Access to Affordable Generics Act - Provisions related to patent settlements S. 1390: STRONGER Patents Act of 2017 - Provisions related to reforms of PTAB proceedings and other patent system reforms Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO S. 2554:Patient Right to Know Drug Prices Act - provisions related to notification of agreements to the FTC and DOJ

H.R. 4710: 340B Protecting Access for the Underserved and Safety-net Entities Act or PAUSE Act - Provisions related to the 340B program H.R. 5598: 340B Optimization Act - Provisions related to transparency in the 340B program H.R. 6071: SERV Communities Act - Provisions related to transparency in the 340B program S. 1131: Fair Accountability and Innovative Research Drug Pricing Act of 2017 - Provisions related to drug pricing S. 2312: HELP Act - Provisions related to 340B program S. 2453: Ensuring the Value of the 340B Program Act of 2018 - Provisions to increase transparency in the 340B program Drug cost and pricing policy issues Transparency policy issues Drug importation and counterfeiting policy issues 340B drug discount program policy issues

H.R. 4710: 340B Protecting Access for the Underserved and Safety-net Entities Act or PAUSE Act - Provisions related to the 340B program H.R. 5598: 340B Optimization Act - Provisions related to transparency in the 340B program H.R. 6071: SERV Communities Act - Provisions related to transparency in the 340B program S. 1131: Fair Accountability and Innovative Research Drug Pricing Act of 2017 - Provisions related to drug pricing S. 2312: HELP Act - Provisions related to 340B program S. 2453: Ensuring the Value of the 340B Program Act of 2018 - Provisions to increase transparency in the 340B program Drug cost and pricing policy issues Transparency policy issues Drug importation and counterfeiting policy issues 340B drug discount program policy issues